Ensysce Biosciences, Inc.

The momentum for this stock is not very good. Ensysce Biosciences, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Ensysce Biosciences, Inc..

News

Ensysce Biosciences announces $5M concurrent offering, shares fall

Seeking Alpha - Healthcare Ensysce Biosciences announces $5M concurrent offering, shares fall...\n more…

Ensysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On?

Benzinga Ensysce Biosciences shares are trading lower by 30% during Thursday's session. The company announced a $5 million registered direct offering and concurrent private placement.\n more…

Ensysce Biosciences to sell 3.55M shares at 47c in registered direct offering

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Globe Newswire New York, NY, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce...\n more…

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Accesswire SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ('Ensysce' or the 'Company'), a clinical-stage pharmaceutical company developing innovative solutions for severe...\n more…

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Accesswire Next Clinical Trial of FDA Breakthrough Therapy PF614-MPAR Supported by $14 Million Federal Government Grant SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. ('Ensysce' or the...\n more…